Quzhuo tongbi formula for reducing gout flare related to uric acid lowering treatment: Study protocol for a multiple-center, randomized, double-blind, placebo, parallel-controlled clinical trial

• Published in: PloS one Vol. 20; no. 7; p. e0327864
• Main Authors: Pan, Hejing, Li, Xuanlin, Wu, Shan, Zhou, Donghai, Guan, Haojie, Wu, Haoyu, Wang, Qiao, Tang, Yujun, Hu, Xuanming, Wang, Meijiao, Zhou, Mingqian, Huang, Runyue, Liu, Lei, Chen, Yaolong, Wen, Chengping, Huang, Lin
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 09.07.2025; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis; Blood; Care and treatment; Causes of; China; Clinical trials; Compliance; Computer and Information Sciences; Consent; Crystals; Disease; Double-Blind Method; Drug dosages; Drug withdrawal; Drugs, Chinese Herbal - therapeutic use; Effectiveness; Electrocardiography; Evaluation; Febuxostat - therapeutic use; Female; Flares; Gout; Gout - blood; Gout - drug therapy; Gout Suppressants - therapeutic use; Health services; Hospitals; Humans; Hyperuricemia; Hyperuricemia - drug therapy; Laboratory tests; Male; Medicine and Health Sciences; Medicine, Chinese; Middle Aged; Multicenter Studies as Topic; Patients; Physical Sciences; Placebos; Prevention; Randomized Controlled Trials as Topic; Research and Analysis Methods; Rheumatic diseases; Rheumatism; Side effects; Steroids; Study Protocol; Traditional Chinese medicine; Uric acid; Uric Acid - blood; Young Adult; China

Gout, a prevalent metabolic rheumatic disease, arises from the accumulation of monosodium urate (MSU) crystals in joints, directly associated with hyperuricemia. Long-term or lifelong urate-lowering therapy (ULT) stands as the primary management strategy. However, there is a significant risk of gout...